Phase II study of erlotinib monotherapy for patients with untreated advanced non-small cell lung cancer, poor performance status and positive EGFR mutation status (OSAKA-LCSG1304)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000011473
- Lead Sponsor
- OSAKA-LCSG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Not provided
(1) Problematic infection that requires anti-biotic, anti-fungal agent or anti-viral agent (2) Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug-induced pneumonia, revealed by chest CT or with clinical symptoms (3) A history of severe hypersensitivity against erlotinib (4) Difficulty in oral administration of erlotinib, functional / organic impairment or inflammatory bowel disease that disturbs absorption of erlotinib (5) Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer (6) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy (7) Psychologically ineligible (8) Decision of ineligibility by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method